Abstracts tagged "lupus nephritis and systemic lupus erythematosus (SLE)"

Abstract Number: 689 • 2017 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients
Ashira Blazer¹, Ida Dzifa Dey², Sara Rasmussen³, Robert M. Clancy⁴ and Jill P. Buyon⁵, ¹Internal Medicine Division of Rheumatology, NYU School of Medicine, New York, NY, ²Internal Medicine, Rheumatology, The University of Ghana, Accra, Ghana, ³Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2 are enriched in African populations due to a conferred resistance to Trypanosoma brucei. This…
Abstract Number: 1267 • 2017 ACR/ARHP Annual Meeting
Blood Pressure Control over Time in Childhood-Onset Systemic Lupus Erythematous
Pinar Ozge Avar Aydin¹, Jian Shan², Hermine I. Brunner¹ and Mark Mitsnefes³, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Peking Union Medical College Hospital, Peking, China, Peking, China, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of increased long-term morbidity and mortality in systemic lupus erythematosus (SLE). As an important modifiable risk factor…
Abstract Number: 1641 • 2017 ACR/ARHP Annual Meeting
Indications for Initial Renal Biopsy in Systemic Lupus Erythematosus: A Systematic Review of the Literature
Andrew McKinnon¹, Annaliese Tisseverasinghe², Susan Barr³, Paul R. Fortin⁴, John G. Hanly⁵, Stephanie Keeling⁶ and Christine A. Peschken², ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁵Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁶Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). An initial renal biopsy (RB) is…
Abstract Number: 776 • 2016 ACR/ARHP Annual Meeting
Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique
Charles Cartou¹, Katlyne Polomat², Florence MOINET², Serge ARFI³, Lauren Brunier-Agot⁴, Marie Blattery⁵, Aymeric Couturier⁶, Georges JEAN BAPTISTE⁷, Michel De Bandt⁸ and Christophe Deligny⁹, ¹nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ²Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ³University Hospital, CHU Fort de France, Fort de France, Martinique, ⁴Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ⁵rheumatology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁶nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸CHU Fort de France, Fort de France, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: There is no data on the efficacy of the EUROLUPUS regimen associated with initial low steroids daily dose in African descent patients with proliferative…
Abstract Number: 964 • 2016 ACR/ARHP Annual Meeting
Tubulointerstitial Damage Is an Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild to Moderate Renal Impairment
Bojana Jovanovic¹, Hina N. Khan¹, Wenzhu Mowrey¹, Peter M. Izmirly², Daniel Schwartz¹, Jill P. Buyon³, Chaim Putterman¹, Beatrice Goilav¹ and Anna R. Broder¹, ¹Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Tubulointerstitial damage (TID) is considered to be a later sequela of lupus nephritis (LN). The clinical significance of TID in patients with only…
Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Gaurav Gulati¹, Michael Bennett², Khalid Abulaban^3,4, Qing Ma⁵, Marisa S. Klein-Gitelman⁶, Kelly A. Rouster-Stevens⁷, Christopher Haffner⁵, Kasha Wiley⁸, Stacy P. Ardoin⁹, Jun Ying¹⁰, Prasad Devarajan¹¹ and Hermine I. Brunner⁸, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Helen DeVos Children's Hospital, Grand Rapids, MI, ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ¹⁰Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…
Abstract Number: 2062 • 2016 ACR/ARHP Annual Meeting
Increased Expression of Response Gene to Complement-32 in Kidney Biopsies from Patients with Lupus Nephritis
Julie Yip¹, Vinh Nguyen², Alexandru Tatomir^3,4, Armugam Mekala^4,5, Dallas Boodhou⁴, Horea Rus^3,4, Cinthia Drachenberg⁶ and Violeta Rus^5,7, ¹Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Medicine, University of Maryland School of Medicine, Baltimore, MD, ³Neurology, Research Service, VAMHCS, Baltimore, MD, ⁴Neurology, University of Maryland School of Medicine, Baltimore, MD, ⁵Research Service, VAMHCS, Baltimore, MD, ⁶Pathology, University of Maryland School of Medicine, Baltimore, MD, ⁷Medicine/Rheum & Clinc Immun, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator widely expressed in normal tissues including brain, kidney, spleen, thymus, multiple tumors and in…
Abstract Number: 2795 • 2016 ACR/ARHP Annual Meeting
Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes
Jorge Medina-Rosas¹, Dafna D. Gladman², Jiandong Su³, Murray Urowitz² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis (LN) and it is an independent prognostic factor of long term outcomes. Recovery from…
Abstract Number: 2820 • 2016 ACR/ARHP Annual Meeting
Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis
Samantha Stanley¹, Huihua Ding², Claudia Pedroza³, Ramesh Saxena⁴, Michelle Petri⁵ and Chandra Mohan¹, ¹Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering Department, University of Houston, Houston, TX, ³Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁴Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An aptamer-based screening assay was used to analyze the levels of 1129 different proteins in 24 human urine samples (8 active lupus nephritis (LN),…
Abstract Number: 2858 • 2016 ACR/ARHP Annual Meeting
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Huihua Ding¹, Ling Qin¹, Samantha Stanley¹, Ramesh Saxena² and Chandra Mohan³, ¹Biomedical Engineering Department, University of Houston, Houston, TX, ²Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is the leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). The objective of this study is to validate…
Abstract Number: 2882 • 2016 ACR/ARHP Annual Meeting
CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis – an Imbalance Towards a Predominant Th1 Response?
Danilo Mesquita Jr.¹, Marcello Fabiano Franco², Gianna Mastroianni Kirsztajn¹, Luciana Aparecida Reis¹, Sandro Perazzio³, Fernanda Vieira Mesquita¹, Vanessa Ferreira¹, Luis E C Andrade⁴ and Alexandre W.S. Souza⁵, ¹Internal Medicine, Universidade Federal de São Paulo, São Paulo, Brazil, ²Pathology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁵Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the involvement of multiple organs and systems with aberrations in T cell response,…
Abstract Number: 2070 • 2015 ACR/ARHP Annual Meeting
Urinary Biomarker Based “a-RAIL”� Study in Adults with Lupus Nephritis
Gaurav Gulati¹, Khalid Abulaban², Jun Ying³, Huijuan Song⁴, Xiaolan Zhang⁵, Qing Ma⁶, Christopher Haffner⁶, Kasha Wiley⁷, Michael Bennett⁸, Brad H. Rovin⁴ and Hermine I. Brunner⁹, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati, Cincinnati, OH, ⁴Ohio State University Medical Center, Columbus, OH, ⁵Ohio State University, Columbus, OH, ⁶Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The present study was aimed at developing an adult Renal Activity In Lupus (A-RAIL) algorithm for Lupus Nephritis (LN) activity assessment using urinary biomarkers…
Abstract Number: 2898 • 2015 ACR/ARHP Annual Meeting
Erythrocytes, Acanthocytes, and Proteins in Urine Reflect Lupus Nephritis Histology
Marco Ulises Martinez-Martinez¹, Lilia Llamazares-Azuara², David Martínez-Galla³, Francisco Valadez-Castillo⁴, Peter Mandeville⁴, Jaime Antonio Borjas García⁵ and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Laboratorio Renal, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³Patología, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁴Faculty of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁵Regional Unit of Rheumatology and Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: Hematuria in lupus nephritis (LN) is secondary to the passage of red blood cells (RBCs) through glomerular abnormalities. Dysmorphic RBCs are associated with glomerulonephritis,…
Abstract Number: 2911 • 2015 ACR/ARHP Annual Meeting
Tubulointerstitial Involvement in Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Tubulointerstitial disease is frequent in lupus nephritis (LN) with immune deposits being present in up to one third of patients.[1,2] Lesions including interstitial infiltration,…
Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Krishan Gupta¹, Manish Rathi², Navin Pattanashetti³, Ritambhra Nada⁴ and Aman Sharma⁵, ¹Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Junior Resident, Chandigarh, India, ⁴Histopathology, Professor, Chandigarh, India, ⁵Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].